Logical Therapeutics Appoints Peter A. Lankau as CEO and Director

Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs.
naproxen and Achievement of Financing Milestone

WALTHAM, Mass., May 11 /PRNewswire/ -- Logical Therapeutics, Inc (Logical), a
biotechnology company focused on the development of products that treat
diseases associated with inflammation, today announced that Peter A. Lankau
has been appointed Chief Executive Officer, and has been elected to the
Company's Board of Directors. Mr. Lankau was most recently President and CEO
of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical
company.

"I am excited to be teaming up with such an experienced group of scientists
and investors to develop clinically meaningful and novel products for
inflammatory diseases," said Mr. Lankau. "Logical Therapeutics' pipeline
includes important medicines for the millions of people who suffer from
chronic inflammatory conditions. Logical's lead compound, LT-NS001 will be
particularly important for patients whose need for non-steroidal
anti-inflammatory treatment is complicated by significant gastrointestinal
risks."

Mr. Lankau became President and CEO of Endo Pharmaceuticals in 2005, after
having served as President and COO since 2003, and SVP of Commercial Business
since 2000. Previously, Mr. Lankau was Vice President, Sales and Marketing at
Alpharma, Inc. and held various management positions at Rhone-Poulenc Rorer.

"We are delighted to have Peter join the Logical team and our Board of
Directors," said Lutz Giebel, Chairman of Logical Therapeutics, Inc., and the
Managing Partner of SV Life Sciences Advisers LLC, a lead investor in Logical,
"His experience in leading a growth oriented public company, his execution of
numerous business development transactions, and his understanding of the
commercially important, and value creating elements of drug development, will
help propel Logical toward significant business opportunities in the future."

Top Line Study Results

Logical also announced the reporting of data from its double-blind,
randomized, active comparator study of LT-NS001 vs. naproxen, in subjects 45
to 70 years of age. LT-NS001 is a novel, patented NCE pro-drug of the popular
non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being
developed to significantly reduce the GI safety risks, including the formation
of ulcers, associated with naproxen.

In the study, subjects underwent upper endoscopies at baseline and on day
seven. Subjects receiving LT-NS001 experienced statistically significantly
fewer endoscopically confirmed gastric ulcers compared to subjects receiving
naproxen. The full results from this study will be presented at scientific
meeting during the third quarter of 2009. See below for additional
information on LT-NS001.

Financing Milestone Achieved

As a result of completing this proof-of-concept study demonstrating the
improved GI safety of LT-NS001 in humans, Logical Therapeutics has
successfully completed all of the milestones associated with its Series B
financing round. Logical intends to continue to progress the clinical
development of LT-NS001, as well as its other programs, to fully explore their
commercial potential as candidates for partnering.

About LT-NS001

LT-NS001 is a novel, patented NCE pro-drug of the popular non-steroidal
anti-inflammatory drug (NSAID) naproxen, which is being developed by Logical
Therapeutics to significantly decrease the GI safety risks associated with
naproxen. Naproxen is widely regarded as the NSAID with the most favorable
cardiovascular safety profile among all of the drugs in this class.

LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once
absorbed into the bloodstream, it is converted rapidly and quantitatively to
naproxen. It is being developed to provide therapeutic levels of naproxen
while avoiding high local concentrations of naproxen in the GI tract, thereby
reducing the local GI toxicity associated with conventional naproxen.

In pre-clinical studies, LT-NS001 has demonstrated significantly less damage
to the gastrointestinal tract than equimolar doses of naproxen.

LT-NS001 has been studied in various randomized controlled single-dose and
multiple-dose clinical studies. In all cases, there were no serious adverse
events and LT-NS001 was well tolerated. Moreover, when the subjects were
dosed twice daily with LT-NS001, plasma concentrations of naproxen were within
the therapeutic range.

The use of NSAIDs is associated with serious side effects, the most frequent
being an increased rate of gastric and duodenal ulcers. In the United States
alone, the direct costs of treating ulcer complications associated with NSAID
use exceed $4 billion a year. Serious NSAID-induced gastrointestinal (GI)
complications, such as hemorrhage and perforation, are directly responsible
for approximately 20,000 deaths per year in the United States.

Logical Therapeutics is developing LT-NS001 under an exclusive license from
Medinox, Inc.

About Logical Therapeutics Inc.

Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed,
privately held biotechnology company focused on the development of products
that treat diseases associated with inflammation. Logical's investors include
S V Life Sciences, Burrill and Company, Novo Ventures A/S, and Novitas
Capital. For more information on Logical Therapeutics, visit the company's
website at www.logicaltherapeutics.com.

Inquiries regarding LT-NS001 should be addressed to our business development
department at bd@logicaltherapeutics.com

SOURCE Logical Therapeutics, Inc.

Nicole Loring of Zer0 to 5ive LLC, +1-617-834-2190, nicole@0to5.com, for
Logical Therapeutics, Inc.